Celecor Therapeutics Inc.
- Address
- 1155 Camino Del Mar, Suit 481
Sponsor Overview
Specializations
Cardiovascular Emergency Care
Celecor Therapeutics Inc. is focused on acute cardiovascular intervention in the setting of ST-segment elevation myocardial infarction (STEMI), with research centered on patients presenting with ongoing ischemic chest pain and diagnostic electrocardiographic changes.
- Acute myocardial infarction
- Pre-hospital treatment
- Ischemic chest pain
- Electrocardiographic ST-segment elevation
The sponsor’s clinical activity is directed toward urgent treatment pathways for suspected heart attack care across multiple active sites.
Thrombotic and Platelet-Targeted Therapy
The research portfolio reflects interest in therapies aimed at limiting coronary thrombosis during the earliest phase of myocardial infarction, with attention to rapid antiplatelet intervention before hospital arrival.
- Coronary thrombosis
- Platelet inhibition
- Antithrombotic therapy
- Early reperfusion support
Clinical interest extends to treatment approaches designed for immediate use in the field, where time-sensitive control of clot-related complications is central.
Acute Coronary Syndrome Outcomes
Trials funded by the sponsor examine short-term clinical outcomes after treatment in presumed acute coronary syndrome, with a particular emphasis on 30-day recovery following intervention in patients with suspected STEMI.
- 30-day clinical outcomes
- Cardiac event prevention
- Emergency cardiology
- Post-event stabilization
Its research activity is concentrated on near-term efficacy endpoints relevant to urgent cardiac care.
Bleeding Risk and Hemostasis
A key area of interest is the assessment of bleeding events associated with antithrombotic treatment in the emergency management of STEMI, including clinically significant hemorrhagic complications.
- Hemorrhagic safety
- Severe bleeding events
- Cardiovascular safety
- Risk-benefit evaluation
This safety focus is relevant to therapies intended for rapid deployment in patients with suspected coronary occlusion.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Phase 3 Randomized, Placebo-Controlled Study on the Efficacy and Safety of Zalunfiban in Pre-Hospital ST-Elevation Myocardial Infarction Patients |  Czechia France Hungary Romania The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 37 sites across their trial portfolio.
Therapeutic Focus
- 1.Cardiovascular Diseases1 trial359 other sponsors
Partnered Research Centres
37 centres- Address
- Molengracht 21, 4818 CK Breda
- Address
- 264 Rue Saint Pierre, 13005 Marseille
- Address
- Num Voie 47 A 83, 47 Boulevard De L Hopital, 75013 Paris
- Address
- Nyiri Ut 38, 6000 Kecskemét
- Address
- 1, place Jules Renard, BP 31, cedex17, 75823 Paris
- Address
- 56 Boulevard De La Boissiere, 93100 Montreuil
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Celecor Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.